+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 30Days +
All Genders
ID04065399

Study of Oral Revumenib in Relapsed or Refractory Leukemias Including MLLKMT2A Gene Rearrangement or NPM1 Mutation Patients

Led by Syndax Pharmaceuticals · Updated on 2026-10-09

447

Participants Needed

57

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying revumenib in participants with relapsed or refractory acute leukemias, including those with specific genetic changes like MLLKMT2A gene rearrangement or NPM1 mutation. This Phase 12 trial aims to find the highest safe dose and recommended dose for Phase 2, then evaluate how well revumenib works and how safe it is in different groups of acute leukemia patients. In Phase 1, participants receive oral revumenib in six different groups based on their use of other medications affecting liver enzymes or antifungal treatments. One group also receives cobicistat daily along with revumenib. Phase 2 includes four specific groups of participants with different types of acute leukemia or genetic mutations, all receiving revumenib to assess its effects and safety over time. Participants will be closely monitored throughout the study with blood tests, physical exams, and assessments to track side effects and measure how the leukemia responds to treatment. The study measures include dose-limiting toxicities, adverse events, drug levels in the blood, and leukemia response rates. This careful monitoring continues for up to several years to understand the long-term effects and safety of revumenib.

CONDITIONS

Brief Title

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Research Team

S

Syndax Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here